Latest Aegis Therapeutics LLC Stories
Aegis Therapeutics LLC announced today that preclinical data was presented at the 2008 International Congress of Endocrinology in Rio de Janeiro, Brasil demonstrating that its Intravail(R) formulation technology provides unmatched non-invasive delivery of the OB-3 peptide, a peptide previously shown to control weight gain and glucose levels in an animal model of diabetes.
Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.
Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent 7,425,542, titled "Stabilizing alkylglycoside compositions and methods thereof." The patent provides broad protection for stabilized human growth hormone (hGH) formulations.
- An uxorious, effeminate, or spiritless man.
- A timorous, cowardly fellow.